• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

    4/20/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    McKesson Corporation (NYSE:MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of Apollo ("Apollo Funds"), under which Apollo Funds will acquire a minority ownership interest in McKesson's Medical-Surgical Solutions ("MMS") business. This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering.

    Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson will retain operating control and majority ownership of MMS and consolidate the results for financial reporting. The transaction is subject to regulatory approvals and customary closing conditions.

    "This transaction marks a key milestone in McKesson's planned separation of MMS," said Brian Tyler, chief executive officer of McKesson. "We are pleased to welcome Apollo as an important strategic and financial partner. Apollo's experience in supporting complex carve-out and public market transactions will be additive as we position MMS for success, while maintaining McKesson's financial and strategic flexibility. We look forward to working together to execute the separation in a manner that maximizes shareholder value, and establishing a well-capitalized, world-class medical surgical supply and solutions company."

    "MMS is a leading healthcare platform with a talented team and strong market position, playing a key role in healthcare supply chain resiliency across non-acute care settings," said Apollo Partner Maxwell David and Managing Director Jeff Armstrong. "We believe the business is well positioned for continued growth, and that Apollo's Hybrid platform enables us to provide flexible, scaled capital to support the next phase of development as MMS prepares to operate as a standalone company."

    Cautionary Statements

    Statements in this press release about of the anticipated completion of Apollo's investment in MMS, McKesson's intent to separate MMS into an independent company, the planned initial public offering ("IPO") of MMS, and the expected benefits of the transactions described, including anticipated timing, plans, expectations, commitments and intentions, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements.

    Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, risk factors include, but are not limited to: Apollo's investment and the planned separation and IPO of MMS are contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; unanticipated business, market, governmental, or other developments could delay or prevent completion of Apollo's investment, the separation, or the IPO, or cause any of the transactions to occur on less favorable terms; the transactions described are subject to conditions that may not be satisfied on the expected timeline, or at all, which could delay or prevent closing; we may be unsuccessful in achieving our strategic growth objectives; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events. We encourage investors to read the important risk factors described in McKesson's most recent Form 10-K filed with the Securities and Exchange Commission.

    About McKesson Corporation

    McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

    About Apollo

    Apollo is a high-growth, global alternative asset manager. Apollo's asset management business seeks to provide its clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, Apollo's investing expertise across its fully integrated platform has served the financial return needs of its clients and provided businesses with innovative capital solutions for growth. Athene, Apollo's retirement services business, specializes in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Apollo's patient, creative, and knowledgeable approach to investing aligns its clients, the businesses it invests in, its employees, and the communities it impacts, to expand opportunity and achieve positive outcomes. As of December 31, 2025, Apollo had approximately $938 billion of assets under management. To learn more, please visit www.apollo.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260419371419/en/

    McKesson Corporation

    Investors

    [email protected]

    Media Relations

    [email protected]

    Apollo

    Noah Gunn

    Global Head of Investor Relations

    Apollo Global Management, Inc.

    (212) 822-0540

    [email protected]

    Joanna Rose

    Global Head of Corporate Communications

    Apollo Global Management, Inc.

    (212) 822-0491

    [email protected]

    Get the next $MCK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/9/2025$960.00Overweight
    Barclays
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    More analyst ratings

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

    McKesson Corporation (NYSE:MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of Apollo ("Apollo Funds"), under which Apollo Funds will acquire a minority ownership interest in McKesson's Medical-Surgical Solutions ("MMS") business. This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering. Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. Mc

    4/20/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

    McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru

    3/6/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Announces Planned CFO Transition

    Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation

    3/5/26 8:10:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on McKesson with a new price target

    Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $960.00

    12/9/25 8:51:34 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Mizuho resumed coverage on McKesson with a new price target

    Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

    12/4/24 7:43:38 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

    11/7/24 6:29:13 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fraga Francisco

    3 - MCKESSON CORP (0000927653) (Issuer)

    4/13/26 1:27:53 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    EVP and Chief Legal Officer Lau Michele sold $2,697,750 worth of shares (2,725 units at $990.00), decreasing direct ownership by 46% to 3,247 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    3/4/26 12:41:44 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Director Martinez Maria sold $328,013 worth of shares (349 units at $939.87), decreasing direct ownership by 54% to 301 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    2/23/26 1:13:41 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    SEC Filings

    View All

    McKesson Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    4/6/26 8:03:56 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by McKesson Corporation

    SCHEDULE 13G/A - MCKESSON CORP (0000927653) (Subject)

    3/27/26 10:33:54 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    3/6/26 8:04:16 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    View All

    McKesson Announces Planned CFO Transition

    Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation

    3/5/26 8:10:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

    Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

    8/26/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

    10/4/23 4:05:00 PM ET
    $KRMD
    $MCK
    Medical/Dental Instruments
    Health Care
    Other Pharmaceuticals

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/13/24 5:09:38 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    1/25/24 1:48:52 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/10/22 8:27:59 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Financials

    Live finance-specific insights

    View All

    McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

    McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru

    3/6/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

    2/4/26 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Declares Quarterly Dividend

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r

    1/28/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care